LINE241220P50000
- 0.00
- 0.000.00%
Lineage Newsroom
J.P. Morgan Remains a Buy on Lineage, Inc. (LINE)
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Lineage Explores Connection Between Food Infrastructure and Economic Development in New Research by Economist Impact
Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.
Trump Media Saw the Largest Increase in Short Interest in October
Lineage Cell Therapeutics Entered Into Definitive Agreements With Certain Institutional Investors And With Broadwood Partners, L.P. For The Purchase And Sale Of Up To An Aggregate Of 39,473,688 Of Lineage's Common Shares And Accompanying Warrants To...
Express News | Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
Wells Fargo Maintains Lineage(LINE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
REITs See Q3 FFO Decline Y/Y Despite Higher Net Operating Income, Occupancy
D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3
Lineage Cell Therapeutics Analyst Ratings
Wells Fargo Remains a Hold on Lineage, Inc. (LINE)
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2024 Earnings Call Transcript Summary
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates
Lineage Cell Therapeutics 3Q Loss/Shr 2c >LCTX
Express News | Lineage Cell Therapeutics Q3 2024 GAAP EPS $(0.02) Beats $(0.04) Estimate, Sales $3.779M Beat $1.033M Estimate
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q3 Revenue $3.8M
Press Release: Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update